ACR 2022 Tweet by David Liew

GM-CSF/mavrilimumab in GCA masterclass from Maria Cid this morning.

Sadly, as John Stone & Sharon Chung ask and Maria Cid reflects on, we're not sure what happens next, despite the promising phase 2 & elegant MOA.
No current plans for a mavrilimumab GCA phase 3
#ACR22 @RheumNow